Pulses are racing!

Posted:
15
September 2004

Excitement is mounting at Richmond Pharmacology as we approach the QTc workshop to be held on 29th September 2004 at St George's Hospital Medical School. The workshop has received much interest and is expected to be a huge success.Richmond Pharmacology has invited main representatives from the top pharmaceutical companies to attend a workshop where world-leading experts in cardiology from St George's Hospital Medical School and also the Medicines and Healthcare Products Regulatory Authority (MHRA) will speak on a range of QTc topics.Studies focussing on the QT interval have become of increased importance recently. A number of drugs have been withdrawn from the market as a result of their capacity to cause potentially fatal arrhythmias associated with the prolongation of the QT interval. Factors influencing the QT interval, regulatory aspects of drug induced QT interval prolongation, correcting or controlling the QT interval, and the definitive QT study will all be discussed, among other topics, at the workshop hosted by Richmond Pharmacology.To find more information on Richmond Pharmacology's QTc capabilities, or for further information on the QTc workshop, follow the link to our QTc studies page.It is not too late to register, please see the workshop page for further information. The QTc Studies page provides up to date information on the services offered by RPL in this area of expertise.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more